Asymptomatic hyperuricemia and gout: Are there any differences (data from a pilot case-control study) by M. S. Eliseev, E. V. Panina, O. V. Zheliabina

Get full text

Basic therapeutic approaches to the management of hematology/oncology patients with new coronavirus infection (COVID-19) by E. N. Misyurina, E. A. Baryakh, N. F. Frolova, O. N. Kotenko, Z. Yu. Mutovina, S. S. Andreev, T. N. Tolstykh, K. V. Yatskov, E. A. Karimova, A. B. Makeshova, O. A. Rukavitsyn, A. V. Misyurin, Yu. Yu. Polyakov, M. A. Mingalimov, T. S. Chudnova, D. E. Gagloeva, D. D. Ivanova, A. I. Koneva, O. L. Kochneva, E. N. Zotina, E. Yu. Grishina, L. T. Shimanovskaya, V. N. Yakimets, E. I. Zhelnova

Get full text

Disparities in adult asthma outcomes among disaggregated data among Asian Americans in the National Health Interview Survey by Alan Zhang, BS, Neha Soogoor, BS, Talia Crowther, MPH, Sanah Vohra, PhD, MPH, Armaan Jamal, BS, Malathi Srinivasan, MD, Gloria Kim, MD, Karina Kim, AM, Latha Palaniappan, MD, MS, Robert Huang, MD, MS, Lauren E. Eggert, MD

Get full text

Outbreaks of European spruce bark beetle dramatically altered Norway spruce-dominated stands with implications for volant wildlife in the Białowieża Forest, Poland by Andrew Carr, Grzegorz Apoznański, Dorota Dobrowolska, Alek Rachwald

Get full text

Effect of inhalational salbutamol ipratropium combination versus salbutamol in asthmatic children: A meta-analysis by Preethi Tamilarasan, Reenaa Mohan, Jenifer Florence Mary J, Shalini Balamurugan, Kalaiselvan G

Get full text

Non-specific effects of different sham acupuncture methods and their impact on true acupuncture effectiveness in migraine: a protocol for systematic review and network meta-analysi... by Fan Jiang, Haifeng Zhang, Lun Li, Qinhong Zhang, Meng Lin, Yongjian Liu, Yong Fu, Jiahui Yang, Qilin Liu, Meiyi Zhu, Xiumei Yan

“…The primary outcome will be the standardised mean difference (SMD) in migraine frequency measures, allowing for the inclusion of various frequency metrics (eg, migraine attacks, migraine days, headache days). Secondary outcomes will include response rate (≥50% reduction in frequency), days with acute medication use, the number of migraine days per month, pain intensity (measured using tools such as the Visual Analogue Scale or Numeric Rating Scale), and scores from migraine-specific questionnaires, among others. …”
Get full text